Conjugates of IL13Rα2 binding agents and use thereof in cancer treatment
AssigneeThe University of Chicago
InventorsIrina V. Balyasnikova, Maciej S. Lesniak
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe University of Chicago
InventorsIrina V. Balyasnikova, Maciej S. Lesniak
Estimating the term…
Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13Rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13Rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).
A conjugate comprising an IL13Rα2 binding agent covalently linked to an effector domain;
A multispecific molecule comprising an IL13Rα2 binding agent covalently linked to a peptide providing a second function, wherein the IL13Rα2 binding agent comprises:
Dependencies are inferred from the claim text.